These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 14654535

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG, Lee SJ, Huh JS, Lee JH.
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Prophylactic effect of pirarubicin (THP) on postoperative recurrence of superficial bladder cancer in terms of intravesical retention time].
    Nonomura N, Nishimura K, Okuyama A, Miki T, Kishimoto T, Kiyohara H, Wakatsuki A, Fujioka H, Kuroda H, Nakano E, Takeyama M, Koide T, Yamaguchi S.
    Hinyokika Kiyo; 2001 May; 47(5):315-9. PubMed ID: 11433751
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience.
    Karakiewicz PI, Benayoun S, Lewinshtein DJ, Chun FK, Shahrour K, Perrotte P.
    Can J Urol; 2006 Aug; 13(4):3189-94. PubMed ID: 16952327
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
    Stoehr B, Mueller T, Granig T, Zangerl F, Steiner H.
    BJU Int; 2008 Dec; 102(11):1556-9. PubMed ID: 18691179
    [Abstract] [Full Text] [Related]

  • 39. [Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
    Segawa N, Nishida T, Takahara K, Nomi H, Azuma H, Katsuoka Y.
    Hinyokika Kiyo; 2008 Nov; 54(11):711-6. PubMed ID: 19068724
    [Abstract] [Full Text] [Related]

  • 40. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M.
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.